Reporting in Cell, scientists have determined that there are hundreds of crucial, long-non-coding RNA (lncRNA) molecules that ...

A new technology that delivers two halves of a gene separately could enable gene therapy treatments of muscular dystrophies.

Most people don’t enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inhaled. A ...

Neoantigen DNA vaccines are safe and capable of inducing neoantigen-specific immune responses in patients with ...

StitchR, a new gene therapy technique, delivers large genes in two parts to treat muscular dystrophies by restoring critical proteins in animal models.

The Keeneland November Breeding Stock Sale concluded its nine-day run in Lexington Wednesday with vibrant trade from a diverse buying bench leading to across-the-board increases where were highlighted ...

A total of 105 head sold for $8,620,500, with an average of $81,325 and a median of $47,500. The median and average were up ...

To determine the type and severity of a cancer, pathologists typically analyze thin slices of a tumor biopsy under a ...

Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset——Joint poster with Bachem demonstrates ...

Novavax incurred a third-quarter 2024 loss of 76 cents per share, narrower than the Zacks Consensus Estimate of a loss of 87 cents. In the year-ago quarter, the company reported a loss of $1.26 per ...